Clinical Trials Browser

Interventional × Neurofibromatosis 1 × CNS × Clear all

NCT03190915 2026-05-27

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Phase 2 Active not recruiting

10 enrolled 11 charts

CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT03433183 2026-05-27

SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors

Phase 2 Completed

21 enrolled 12 charts

Neurofibromatosis 1, Neurofibrosarcoma

NCT01362803 2026-05-22

AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors

Phase 1/2 Active not recruiting

99 enrolled 1 FDA

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT05101148 2026-05-20

Phase I Study to Assess the Effect of Food on the PK and Gastrointestinal Tolerability of Selumetinib in Adolescent Children With Neurofibromatosis Type 1 Related Plexiform Neurofibromas

Phase 1 Active not recruiting

Neurofibromatosis 1

NCT06541847 2026-05-19

INSPIRE-NF1

Phase 2 Recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04590235 2026-05-14

A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)

Phase 1 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06507748 2026-05-14

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

Phase NA Recruiting

Neurofibromatosis 1, Pain, Neurofibroma, Plexiform

NCT01089101 2026-05-13

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Phase 1/2 Active not recruiting

Astrocytoma, Neurofibromatosis 1

NCT03975829 2026-05-11

Pediatric Long-Term Follow-up and Rollover Study

Phase 4 Recruiting

Astrocytoma, Ganglioneuroma, Glioblastoma, Glioma, Histiocytosis, Langerhans-Cell, Neuroblastoma, Neurofibromatosis 1, Oligodendroglioma, Ganglioglioma, Neurocytoma, Neurofibroma, Plexiform

NCT07102394 2026-05-08

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

Phase 1 Recruiting

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses

NCT04763109 2026-05-07

Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence

Phase NA Recruiting

Neurofibromatosis 1

NCT03962543 2026-05-06

ReNeu

Phase 2 Active not recruiting

114 enrolled 25 charts 1 FDA

Neurofibroma, Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT03363217 2026-04-24

Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.

Phase 2 Active not recruiting

Brain Neoplasms, Glioma, Neurofibromatosis 1, Neurofibroma, Plexiform

NCT04750928 2026-04-24

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

Phase 1/2 Recruiting

Neurofibromatosis 1

NCT06300502 2026-04-22

Assessing the Efficacy of Repeat, Monthly Treatments of Deoxycholate for NF1 Associated Cutaneous Neurofibromas (cNFs)

Phase 1 Enrolling by invitation

Neurofibroma, Neurofibromatosis 1

NCT04481035 2026-04-21

NF1NAC

Phase 2 Completed

5 enrolled 10 charts

Neurofibromatosis 1

NCT05849662 2026-04-15

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Phase 1/2 Recruiting

CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT03871257 2026-04-13

A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and Low-Grade Glioma

Phase 3 Active not recruiting

Neurofibromatosis 1

NCT07521657 2026-04-13

NF118

Phase 2 Not yet recruiting

Glioblastoma, Glioma, Neurofibromatosis 1

NCT05735717 2026-04-06

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Phase 2 Recruiting

CNSClassical hematologyLymphoidOther hematologic neoplasm

Chromosome 7, monosomy, Anemia, Refractory, with Excess of Blasts, Chromosome Aberrations, Influenza, Human, Neurofibromatosis 1, Leukemia, Myeloid, Acute, beta-Thalassemia, Neoplasm, Residual, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT04924608 2026-03-23

KOMET

Phase 3 Active not recruiting

145 enrolled 17 charts 1 FDA

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06188741 2026-03-12

NF114

Phase 2 Recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06502171 2026-03-12

NF113

Phase 1 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02407405 2026-03-05

MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

Phase 2 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT06934928 2026-03-05

Assessing the Efficacy of Repeat, Monthly Treatments of Alexandrite Laser for NF1-associated Cutaneous Neurofibromas (cNFs)

Phase NA Suspended

Neurofibromatosis 1, Neurofibromatoses

NCT07233408 2026-02-27

Tailoring an Online Platform to Promote Evidence-Based Care for Adults With Neurofibromatosis 1 and Low Health Literacy

Phase NA Recruiting

Neurofibromatosis 1, Neurofibromatoses

NCT05361811 2026-02-19

Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial

Phase NA Recruiting

CNSDermatologic

Cardiofaciocutaneous syndrome, Legius syndrome, Neurofibromatosis 1, Noonan Syndrome, Genetic Diseases, Inborn, Costello Syndrome

NCT05005845 2026-02-17

NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF)

Phase 2 Completed

199 enrolled 15 charts

Neurofibromatosis 1

NCT05253131 2026-02-11

Trial of Selumetinib and Bromodomain Inhibitor With Durvalumab for Sarcomas

Phase 2 Not yet recruiting

Neurofibromatosis 1, Sarcoma, Neurofibrosarcoma

NCT05363267 2026-01-13

NF-1, Nutraceutical Intervention

Phase 1 Active not recruiting

Neurofibromatosis 1

NCT03406208 2025-12-24

Resiliency Training for Adults With Neurofibromatosis Via Live Videoconferencing

Phase NA Completed

Schwannomatosis, Behavior, Neurofibromatosis 1, Neurofibromatosis 2, Neurofibromatoses

NCT05309668 2025-12-18

SPRINKLE

Phase 1/2 Active not recruiting

36 enrolled 37 charts

Neurofibromatosis 1

NCT06961565 2025-12-04

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

Phase 1 Recruiting

Neurofibromatosis 1, Neurofibromatoses, Neurofibroma, Plexiform

NCT06132165 2025-11-21

Efficacy of Skin Cooling in Reducing Pain Associated With Non-invasive Treatments of Neurofibromatosis Type 1 Cutaneous Neurofibromas

Phase 1 Completed

Neurofibromatosis 1

NCT06262113 2025-10-03

A Decentralized Clinical Trial to Promote Evidence-Based Care for Underserved Patients With Neurofibromatosis 1

Phase NA Recruiting

Neurofibromatosis 1, Neurofibromatoses

NCT07077408 2025-07-22

iCanCope With NF: Innovating an Efficacious Digital Self-management and Transitional Care Program for Adolescents With Neurofibromatosis

Phase NA Not yet recruiting

Neurofibromatosis 1

NCT00624234 2025-07-08

Neurobiology and Treatment of Reading Disability in NF-1

Phase NA Completed

184 enrolled 10 charts

Dyslexia, Learning Disabilities, Neurofibromatosis 1

NCT06735820 2025-07-03

MEKMDM2

Phase 1/2 Not yet recruiting

Neurofibromatosis 1, Neurofibrosarcoma

NCT02964884 2025-06-24

Interventions for Reading Disabilities in NF1

Phase 2 Active not recruiting

Dyslexia, Learning Disabilities, Neurofibromatosis 1

NCT07024394 2025-06-17

Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1

Phase 1/2 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT02728388 2025-05-08

Photodynamic Therapy for Benign Dermal Neurofibromas- Phase II

Phase 2 Recruiting

Neurofibroma, Neurofibromatosis 1

NCT03231306 2025-05-02

NF108-BINI

Phase 2 Completed

45 enrolled 8 charts

Neurofibroma, Neurofibromatosis 1, Peripheral Nervous System Neoplasms, Neurofibromatoses, Neurofibroma, Plexiform

NCT04561765 2025-03-30

Innovation in the Treatment of Persistent Pain in Adults With NF1: Implementation of the iCanCope Mobile Application- Clinical Trial

Phase NA Completed

122 enrolled 21 charts

Neurofibromatosis 1, Chronic Pain

NCT05913037 2025-03-06

FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas

Phase 3 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT05196854 2025-02-24

Clinical Hypnosis and Home Blood Pressure Monitoring in Children With Neurofibromatosis Type 1

Phase NA Completed

Hypertension, Neurofibromatosis 1, Neurofibromatoses

NCT04730583 2025-02-21

Tolerability of Device Based Therapies for Neurofibromatosis Type 1 Cutaneous Neurofibromas

Phase 1 Completed

Neurofibromatosis 1

NCT06120036 2025-02-21

Dosing and Tolerability of Deoxycholic Acid vs. Polidocanol in the Treatment of Neurofibromatosis Type 1 Cutaneous Neurofibromas

Phase 1 Completed

Neurofibromatosis 1

NCT06763315 2025-01-08

LS-NF1PNs

Phase 2 Not yet recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform

NCT01553149 2025-01-07

Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

Phase 2 Completed

75 enrolled 17 charts

Astrocytoma, Neurofibromatosis 1, Optic Nerve Glioma

NCT04954001 2024-11-12

Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1

Phase 1/2 Active not recruiting

Neurofibromatosis 1, Neurofibroma, Plexiform